A. Szczęsna

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

U. Gatzemeier, A Płużańska, A. Szczęsna et al. · Journal of Clinical Oncology · 2004 · 300 citations

Medicine, Oncology, Pharmacology +15

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Rafael Rosell, G. Robinet, A. Szczęsna et al. · Annals of Oncology · 2007 · 260 citations · Full text

Medicine, Oncology, Pharmacology +15

FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

Robert Pirker, A. Szczęsna, Joachim von Pawel et al. · Journal of Clinical Oncology · 2008 · 173 citations

Medicine, Oncology, Pharmacology +17

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease

Petr Zatloukal, F. Cardenal, A. Szczęsna et al. · Annals of Oncology · 2010 · 150 citations · Full text

Medicine, Oncology, Pharmacology +13

Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)

Rafael Rosell, Catherine Daniel, Rodryg Ramlau et al. · Journal of Clinical Oncology · 2004 · 134 citations

Medicine, Oncology, Pharmacology +16